Home > Boards > US Listed > Biotechs > AEterna Zentaris Inc. (AEZS)

Actually good news. Conversion ratio will probably be

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
jaybird249 Member Profile
 
Followed By 80
Posts 2,931
Boards Moderated 0
Alias Born 05/05/06
160x600 placeholder
Aeterna Zentaris revenue in-line Seeking Alpha - 11/4/2021 5:24:08 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/4/2021 4:17:19 PM
Aeterna Zentaris Reports Third Quarter 2021 Financial Results and Provides Pipeline Program Updates GlobeNewswire Inc. - 11/4/2021 4:05:00 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/7/2021 8:01:35 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 9/13/2021 7:02:09 AM
Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire Inc. - 9/8/2021 8:00:00 AM
Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates GlobeNewswire Inc. - 8/4/2021 4:05:00 PM
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing GlobeNewswire Inc. - 7/29/2021 8:05:00 AM
Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs GlobeNewswire Inc. - 6/7/2021 8:05:00 AM
Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit GlobeNewswire Inc. - 6/3/2021 8:05:00 AM
Aeterna Zentaris starts preclinical development of macimorelin in amyotrophic lateral sclerosis Seeking Alpha - 5/17/2021 9:00:19 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/17/2021 8:16:56 AM
Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential... GlobeNewswire Inc. - 5/17/2021 8:05:00 AM
Aeterna Zentaris commences late-stage growth hormone deficiency trial Seeking Alpha - 5/13/2021 8:26:05 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/13/2021 8:15:46 AM
Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency GlobeNewswire Inc. - 5/13/2021 8:05:00 AM
Aeterna Zentaris to Present at the Q2 Virtual Investor Summit GlobeNewswire Inc. - 5/10/2021 8:05:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/6/2021 11:24:16 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/6/2021 11:18:41 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/6/2021 11:12:53 AM
Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Prim... GlobeNewswire Inc. - 5/6/2021 8:05:00 AM
Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders GlobeNewswire Inc. - 5/5/2021 4:35:00 PM
Aeterna Zentaris reports Q1 results Seeking Alpha - 5/5/2021 8:29:40 AM
Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates GlobeNewswire Inc. - 5/5/2021 8:05:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/5/2021 6:05:15 AM
jaybird249   Friday, 10/16/15 07:40:04 AM
Re: None
Post # of 18661 
Actually good news. Conversion ratio will probably be about 25 to 1 for remaining convertible shares so less than 700 million fully diluted shares.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences